Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model

Kenneth Hoyt, Jason M. Warram, Heidi Umphrey, Lin Belt, Sharon Samuel, Karri Folks, Cecil Stockard, Mark Lockhart, Michelle L. Robbin, William Grizzle, Kurt R. Zinn

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

This paper describes preliminary results in a murine model devoted to monitoring breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound (US). Twenty mice were implanted with 2LMP breast cancer cells. Three weeks thereafter, 10 mice were administered a 0.1 mg i.p. injection of bevacizumab whereas the remaining mice received saline injections. Using a Philips iU22 scanner equipped with an L9-3 transducer, baseline and follow-up imaging at day 6 was performed using contrast-enhanced US and flash-replenishment techniques. Contrast agent flow (i.e., time-intensity curves) and tumor reperfusion parameters were derived from US image sequences and a given region-of-interest (ROI). Experimental results showed reperfusion metrics were greater for tumors treated with bevacizumab compared to controls. Significant differences found in the AUC (p < 0.01) and Ipk (p < 0.01) timeintensity curve parameters maybe due to a reduction in intratumoral pressures and restored tumor flow. No significant differences were found between control and treated tumors for either the Tpk parameter (p = 0.20) or tumor size (p = 0.18). Histological results revealed increased microvessel density (MVD) for control tumors (p < 0.01) when compared to treated mice. No significant differences in tumor necrosis levels (p = 0.18) were found between control and therapy tumor groups. Overall, these preliminary experiments demonstrate that changes in tumor vascularity and perfusion kinetics in response to antiangiogenic therapy can be distinguished using contrast-enhanced US techniques.

Original languageEnglish (US)
Title of host publication2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009
DOIs
StatePublished - Dec 1 2009
Event2009 IEEE International Ultrasonics Symposium, IUS 2009 - Rome, Italy
Duration: Sep 20 2009Sep 23 2009

Other

Other2009 IEEE International Ultrasonics Symposium, IUS 2009
CountryItaly
CityRome
Period9/20/099/23/09

Fingerprint

breast
tumors
cancer
mice
therapy
injection
replenishment
necrosis
curves
scanners
flash
transducers
kinetics

Keywords

  • Bevacizumab
  • Breast cancer
  • Contrast agent
  • Ultrasound

ASJC Scopus subject areas

  • Acoustics and Ultrasonics

Cite this

Hoyt, K., Warram, J. M., Umphrey, H., Belt, L., Samuel, S., Folks, K., ... Zinn, K. R. (2009). Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model. In 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009 [5441595] https://doi.org/10.1109/ULTSYM.2009.5441595

Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound : Initial results using a murine model. / Hoyt, Kenneth; Warram, Jason M.; Umphrey, Heidi; Belt, Lin; Samuel, Sharon; Folks, Karri; Stockard, Cecil; Lockhart, Mark; Robbin, Michelle L.; Grizzle, William; Zinn, Kurt R.

2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009. 2009. 5441595.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Hoyt, K, Warram, JM, Umphrey, H, Belt, L, Samuel, S, Folks, K, Stockard, C, Lockhart, M, Robbin, ML, Grizzle, W & Zinn, KR 2009, Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model. in 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009., 5441595, 2009 IEEE International Ultrasonics Symposium, IUS 2009, Rome, Italy, 9/20/09. https://doi.org/10.1109/ULTSYM.2009.5441595
Hoyt K, Warram JM, Umphrey H, Belt L, Samuel S, Folks K et al. Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model. In 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009. 2009. 5441595 https://doi.org/10.1109/ULTSYM.2009.5441595
Hoyt, Kenneth ; Warram, Jason M. ; Umphrey, Heidi ; Belt, Lin ; Samuel, Sharon ; Folks, Karri ; Stockard, Cecil ; Lockhart, Mark ; Robbin, Michelle L. ; Grizzle, William ; Zinn, Kurt R. / Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound : Initial results using a murine model. 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009. 2009.
@inproceedings{7ced1ed166a747308d7c2aa546cf5853,
title = "Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model",
abstract = "This paper describes preliminary results in a murine model devoted to monitoring breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound (US). Twenty mice were implanted with 2LMP breast cancer cells. Three weeks thereafter, 10 mice were administered a 0.1 mg i.p. injection of bevacizumab whereas the remaining mice received saline injections. Using a Philips iU22 scanner equipped with an L9-3 transducer, baseline and follow-up imaging at day 6 was performed using contrast-enhanced US and flash-replenishment techniques. Contrast agent flow (i.e., time-intensity curves) and tumor reperfusion parameters were derived from US image sequences and a given region-of-interest (ROI). Experimental results showed reperfusion metrics were greater for tumors treated with bevacizumab compared to controls. Significant differences found in the AUC (p < 0.01) and Ipk (p < 0.01) timeintensity curve parameters maybe due to a reduction in intratumoral pressures and restored tumor flow. No significant differences were found between control and treated tumors for either the Tpk parameter (p = 0.20) or tumor size (p = 0.18). Histological results revealed increased microvessel density (MVD) for control tumors (p < 0.01) when compared to treated mice. No significant differences in tumor necrosis levels (p = 0.18) were found between control and therapy tumor groups. Overall, these preliminary experiments demonstrate that changes in tumor vascularity and perfusion kinetics in response to antiangiogenic therapy can be distinguished using contrast-enhanced US techniques.",
keywords = "Bevacizumab, Breast cancer, Contrast agent, Ultrasound",
author = "Kenneth Hoyt and Warram, {Jason M.} and Heidi Umphrey and Lin Belt and Sharon Samuel and Karri Folks and Cecil Stockard and Mark Lockhart and Robbin, {Michelle L.} and William Grizzle and Zinn, {Kurt R.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1109/ULTSYM.2009.5441595",
language = "English (US)",
isbn = "9781424443895",
booktitle = "2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009",

}

TY - GEN

T1 - Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound

T2 - Initial results using a murine model

AU - Hoyt, Kenneth

AU - Warram, Jason M.

AU - Umphrey, Heidi

AU - Belt, Lin

AU - Samuel, Sharon

AU - Folks, Karri

AU - Stockard, Cecil

AU - Lockhart, Mark

AU - Robbin, Michelle L.

AU - Grizzle, William

AU - Zinn, Kurt R.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - This paper describes preliminary results in a murine model devoted to monitoring breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound (US). Twenty mice were implanted with 2LMP breast cancer cells. Three weeks thereafter, 10 mice were administered a 0.1 mg i.p. injection of bevacizumab whereas the remaining mice received saline injections. Using a Philips iU22 scanner equipped with an L9-3 transducer, baseline and follow-up imaging at day 6 was performed using contrast-enhanced US and flash-replenishment techniques. Contrast agent flow (i.e., time-intensity curves) and tumor reperfusion parameters were derived from US image sequences and a given region-of-interest (ROI). Experimental results showed reperfusion metrics were greater for tumors treated with bevacizumab compared to controls. Significant differences found in the AUC (p < 0.01) and Ipk (p < 0.01) timeintensity curve parameters maybe due to a reduction in intratumoral pressures and restored tumor flow. No significant differences were found between control and treated tumors for either the Tpk parameter (p = 0.20) or tumor size (p = 0.18). Histological results revealed increased microvessel density (MVD) for control tumors (p < 0.01) when compared to treated mice. No significant differences in tumor necrosis levels (p = 0.18) were found between control and therapy tumor groups. Overall, these preliminary experiments demonstrate that changes in tumor vascularity and perfusion kinetics in response to antiangiogenic therapy can be distinguished using contrast-enhanced US techniques.

AB - This paper describes preliminary results in a murine model devoted to monitoring breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound (US). Twenty mice were implanted with 2LMP breast cancer cells. Three weeks thereafter, 10 mice were administered a 0.1 mg i.p. injection of bevacizumab whereas the remaining mice received saline injections. Using a Philips iU22 scanner equipped with an L9-3 transducer, baseline and follow-up imaging at day 6 was performed using contrast-enhanced US and flash-replenishment techniques. Contrast agent flow (i.e., time-intensity curves) and tumor reperfusion parameters were derived from US image sequences and a given region-of-interest (ROI). Experimental results showed reperfusion metrics were greater for tumors treated with bevacizumab compared to controls. Significant differences found in the AUC (p < 0.01) and Ipk (p < 0.01) timeintensity curve parameters maybe due to a reduction in intratumoral pressures and restored tumor flow. No significant differences were found between control and treated tumors for either the Tpk parameter (p = 0.20) or tumor size (p = 0.18). Histological results revealed increased microvessel density (MVD) for control tumors (p < 0.01) when compared to treated mice. No significant differences in tumor necrosis levels (p = 0.18) were found between control and therapy tumor groups. Overall, these preliminary experiments demonstrate that changes in tumor vascularity and perfusion kinetics in response to antiangiogenic therapy can be distinguished using contrast-enhanced US techniques.

KW - Bevacizumab

KW - Breast cancer

KW - Contrast agent

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=77952843977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952843977&partnerID=8YFLogxK

U2 - 10.1109/ULTSYM.2009.5441595

DO - 10.1109/ULTSYM.2009.5441595

M3 - Conference contribution

AN - SCOPUS:77952843977

SN - 9781424443895

BT - 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009

ER -